Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery
| Autor: | Aihui Liao, Yoshinobu Ichiki, Huali Hu, Ruofu Xu, Fenglei Yu, Shuai Zou, Dirk De Ruysscher |
|---|---|
| Přispěvatelé: | Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Conversion therapy Progression-free survival Radical surgery Chemotherapy Lung business.industry General Medicine Immunotherapy medicine.disease CANCER Conversion treatment medicine.anatomical_structure 030220 oncology & carcinogenesis Locally advanced disease immunotherapy neoadjuvant treatment Adenocarcinoma business N3 locally advanced NSCLC |
| Zdroj: | Annals of translational medicine, 7(20):590. AME Publishing Company |
| ISSN: | 2305-5839 |
| DOI: | 10.21037/atm.2019.09.113 |
| Popis: | Patients with N3 non-small cell lung cancer (NSCLC) have unresectable tumors. Although significant progress has been made in the past decades for such tumors, the average median survival time remains at 10 months. Equally dismal long-term survival rates were reported with the average 5-year-suvival rate at 9%. Here, we report on a case of a patient with locally advanced disease that was treated with conversion therapy using targeted anti-PD-1 immunotherapy with platinum-based chemotherapy. Following this therapeutic regimen, the tumor showed a reversion to pN0 from pN3 and the patient showed a progression free survival time of at least 33 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|